KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income - MinorityNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Teva Pharmaceutical Industries (TEVA) Equity Income (2017 - 2025)

Teva Pharmaceutical Industries' Equity Income history spans 9 years, with the latest figure at $11.0 million for Q4 2025.

  • For the quarter ending Q4 2025, Equity Income changed N/A year-over-year to $11.0 million, compared with a TTM value of $13.5 million through Dec 2025, up 1250.0%, and an annual FY2025 reading of $15.0 million, up 1400.0% over the prior year.
  • Equity Income for Q4 2025 was $11.0 million at Teva Pharmaceutical Industries, up from $2.0 million in the prior quarter.
  • The five-year high for Equity Income was $21.0 million in Q1 2022, with the low at -$5.0 million in Q3 2021.
  • Average Equity Income over 5 years is $2.8 million, with a median of $1.0 million recorded in 2022.
  • Year-over-year, Equity Income skyrocketed 600.0% in 2022 and then tumbled 900.0% in 2024.
  • Tracing TEVA's Equity Income over 5 years: stood at -$5.0 million in 2021, then soared by 120.0% to $1.0 million in 2022, then changed by 0.0% to $1.0 million in 2023, then skyrocketed by 200.0% to $3.0 million in 2024, then skyrocketed by 266.67% to $11.0 million in 2025.
  • Per Business Quant, the three most recent readings for TEVA's Equity Income are $11.0 million (Q4 2025), $2.0 million (Q3 2025), and $1.0 million (Q2 2025).